We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-22.69%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$116M
AUM Growth
+$3.75M
Cap. Flow
+$28.9M
Cap. Flow %
24.95%
Top 10 Hldgs %
40.13%
Holding
97
New
21
Increased
22
Reduced
11
Closed
4

Top Buys

Rank Stock Value
1
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$5.4M
2
DERM
Dermira, Inc.
DERM
+$4.22M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$3.03M
4
NVAX icon
Novavax
NVAX
+$2.97M
5
ALDR
Alder Biopharmaceuticals
ALDR
+$2.83M

Top Sells

Rank Stock Value
1
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$3.93M
2
CYTR
CytRx Corp
CYTR
+$1.54M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$725K
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$596K
5
LOXO
Loxo Oncology, Inc
LOXO
+$476K

Sector Composition

Rank Sector Weight
1 Healthcare 73.46%
2 Financials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PVLA
76
Palvella Therapeutics
PVLA
$1.99B
$95K 0.08%
+628
New +$88.3K
GNVC
77
DELISTED
GenVec, Inc.
GNVC
$77K 0.07%
9,580
– –
CVM icon
78
CEL-SCI Corp
CVM
$20.3M
$68K 0.06%
170
– –
SRRA
79
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$67K 0.06%
250
– –
AKTX
80
Akari Therapeutics
AKTX
$13.8M
$66K 0.06%
6
-4
-40% -$41.5K
GLMD icon
81
Galmed Pharmaceuticals
GLMD
$5.13M
$66K 0.06%
75
+8
+12% +$7.84K
ALPN
82
DELISTED
Alpine Immune Sciences Inc
ALPN
$63K 0.05%
3,750
– –
CHEKW
83
DELISTED
Check-Cap Ltd. Series A Warrant
CHEKW
$42K 0.04%
53,690
-73
-0.1% -$50
ATRS
84
DELISTED
Antares Pharma, Inc.
ATRS
$39K 0.03%
45,000
– –
ETRM
85
DELISTED
EnteroMedics Inc.
ETRM
$32K 0.03%
476
– –
NDRM
86
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$17K 0.01%
+1,202
New +$16.2K
TRVN
87
DELISTED
Trevena, Inc.
TRVN
– –
-24
Closed -$155K
ARNA
88
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-38,160
Closed -$725K
CTIC
89
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-319,538
Closed -$3.93M
CYTR
90
DELISTED
CytRx Corp
CYTR
– –
-97,169
Closed -$1.54M
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, DAFNA Capital Management held 97 positions worth $116M, up 3.3% from $112M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

DAFNA Capital Management deployed $28.9M of net new capital in Q1 2016, opening 21 new positions and adding to 22 existing holdings. Its largest new stake was Dermira, Inc.: 171,881 shares worth $3.55M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 77% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Tobira Therapeutics, Inc. Common Stock, an estimated $596K trimmed.

  • DAFNA Capital Management's largest Q1 2016 buy was Dermira, Inc.: 171,881 shares worth $3.55M.
  • DAFNA Capital Management added most to VITAE PHARMACEUTICALS INC COMMON STOCK in Q1 2016, an estimated $5.4M increase.
  • DAFNA Capital Management's biggest Q1 2016 reduction was Tobira Therapeutics, Inc. Common Stock, cutting an estimated $596K.
  • DAFNA Capital Management fully exited CTI BioPharma Corp. (DE) Common Stock in Q1 2016, selling an estimated $3.93M.
  • DAFNA Capital Management's ten largest holdings make up 40% of its $116M portfolio in Q1 2016.
  • DAFNA Capital Management opened 21 new positions and closed 4 in Q1 2016.
  • DAFNA Capital Management's portfolio value rose 3.3% quarter-over-quarter to $116M.

Based on DAFNA Capital Management's 13F filing for Q1 2016, filed 16 May 2016.